Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lymphoma 1Esophageal Squamous Cell Carcinoma 1

Interventions

Cisplatin 21Radiotherapy 16Fluorouracil 16Paclitaxel 15Irinotecan 8Docetaxel 8Neoadjuvant Therapy 6Drug Therapy 5tislelizumab 4sintilimab 4Surgical Procedures, Operative 4Radiation 4Oxaliplatin 4Leucovorin 4Esophagectomy 4Capecitabine 4toripalimab 3pembrolizumab 3TP protocol 3Chemotherapy, Adjuvant 3S 1 (combination) 2Levoleucovorin 2Injections 2Cetuximab 2Carboplatin 2lenvatinib 1irinotecan sucrosofate 1durvalumab 1atropine sulfate-diphenoxylate hydrochloride drug combination 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Esophageal Squamous Cell Carcinoma × atropine sulfate-diphenoxylate hydrochloride drug combination × Clear all
NCT07016737 2025-06-12

ESO-Nanjing12

Jiangsu Cancer Institute & Hospital

Phase 3 Enrolling by invitation
79 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡